Genetic Associations Between Common Medication Use and Osteoporosis-Related Outcomes: A Mendelian Randomization Study
Archives of Medical Science · 04.06.2026
DOI: 10.5114/aoms/218561 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Medical Science, online erschienen am 04.06.2026. Verfasst von Yuxuan Wu und 4 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
Osteoporosis pathogenesis involves a complex interplay of genetic predisposition and medication exposure. Although long-term medication use contributes to bone fragility, which is distinct from osteomalacia, genetic evidence linking common medication-use traits to osteoporosis remains limited. Material and methods Two-sample Mendelian randomization (MR) analyses utilized GWAS data for 22 medication-use traits (UK Biobank) and osteoporosis outcomes (FinnGen R12). Multivariable MR (MVMR) was employed to adjust for confounding by underlying disease indications. Primary estimates were derived using the inverse variance–weighted (IVW) method, supported by comprehensive sensitivity analyses including MR-Egger, weighted median, and MR-PRESSO to evaluate heterogeneity and pleiotropy.
Results
Univariable MR identified seven significant associations: anilide use with increased osteoporosis risk (OR=1.25, FDR=0.0201); immunosuppressant use with higher risks of osteoporosis with pathological fracture (OR=1.16, FDR=0.0074) and drug-induced osteoporosis (OR=1.36, FDR=0.0168); thyroid preparations with increased osteoporosis (OR=1.08, FDR=0.0016), drug-induced osteoporosis, and osteoporosis with pathological fracture; and an inverse association between antidiabetic drug use and osteoporosis (OR=0.88, FDR=0.0002). In MVMR, associations for anilide and thyroid preparation use remained significant after adjusting for back pain and hypothyroidism, respectively. However, the antidiabetic signal reversed after type 2 diabetes adjustment, indicating the observed benefit was likely confounded by the underlying metabolic condition rather than a direct pharmacological effect.
Conclusions
Genetic evidence supports that anilide and thyroid hormone use may independently increase osteoporosis risk, while the protection from antidiabetic therapy is confounded by diabetes status. Medication-related osteoporosis should be considered in long-term pharmacologic management.
Zitieren
APA
Wu, Y., Wang, Z., Chen, X., Chen, X., & Hao, R. (2026). Genetic Associations Between Common Medication Use and Osteoporosis-Related Outcomes: A Mendelian Randomization Study. Archives of Medical Science. https://doi.org/10.5114/aoms/218561
Vancouver
Wu Y, Wang Z, Chen X, Chen X, Hao R. Genetic Associations Between Common Medication Use and Osteoporosis-Related Outcomes: A Mendelian Randomization Study. Archives of Medical Science. 2026. doi:10.5114/aoms/218561
BibTeX
@article{Wu2026,
author = {Wu, Yuxuan and Wang, Zhicong and Chen, Xue and Chen, Xi and Hao, Ran},
title = {Genetic Associations Between Common Medication Use and Osteoporosis-Related Outcomes: A Mendelian Randomization Study},
journal = {Archives of Medical Science},
year = {2026},
doi = {10.5114/aoms/218561}
}
EUVIMED